Terns Pharmaceuticals
NASDAQ · TERN·Foster City, CA·Small-cap·Phase 2
Clinical-stage biotech developing small-molecule therapies for oncology and obesity. Lead asset TERN-701 is an allosteric BCR-ABL inhibitor in Phase 2 for chronic myeloid leukemia; TERN-601 is an oral GLP-1 agonist in development for obesity.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Terns Corporate Presentation March 2026 | Corporate overview | March 1, 2026 | 51 |